We are live on ! Find out more
IMPL

Impel Pharmaceuticals Inc. Common Stock
IMPL

Delisted

IMPL was delisted on the 15th of December, 2023.

Back to rankings

45 hedge funds and large institutions have $132M invested in Impel Pharmaceuticals Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 4 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 4

27% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 11

2% more funds holding

Funds holding: 44 → 45 (+1)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

41% less capital invested

Capital invested by funds: $222M → $132M (-$90.7M)

Holders
45
Holders Change
+1
Holders Change %
+2.27%
% of All Funds
0.69%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
14
Increased
17
Reduced
4
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.08M
2
Two Sigma Investments
Two Sigma Investments
New York
+$1.42M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.27M
4
DA
DCF Advisers
Connecticut
+$1.06M
5
BlackRock
BlackRock
New York
+$862K

Top Sellers

Rank Fund Capital Flow
1
AAP
Ardsley Advisory Partners
Connecticut
-$3.78M
2
Russell Investments Group
Russell Investments Group
United Kingdom
-$2.44M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.69M
4
WP
Woodline Partners
California
-$1.22M
5
Victory Capital Management
Victory Capital Management
Texas
-$979K
Name Holding Trade Value Shares
Change 		Change in
Stake
KKRC
1
Kohlberg Kravis Roberts & Co
New York
$35.7M – – –
5VM
2
5AM Venture Management
California
$24.9M – – –
VC
3
Vivo Capital
California
$24.9M – – –
VP
4
venBio Partners
California
$23.8M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$4.24M +$1.27M +127,211 +35%
BlackRock
6
BlackRock
New York
$3.06M +$862K +86,347 +32%
LM
7
Lasry Marc
$2.85M – – –
DA
8
DCF Advisers
Connecticut
$2.21M +$1.06M +106,027 +71%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$1.8M +$2.08M +208,760 New
State Street
10
State Street
Massachusetts
$1.46M +$399K +39,964 +31%
Two Sigma Investments
11
Two Sigma Investments
New York
$1.23M +$1.42M +142,098 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.11M +$109K +10,884 +9%
BCM
13
Bridgeway Capital Management
Texas
$676K +$782K +78,300 New
Two Sigma Advisers
14
Two Sigma Advisers
New York
$504K +$583K +58,400 New
Bank of New York Mellon
15
Bank of New York Mellon
New York
$427K +$151K +15,078 +44%
Northern Trust
16
Northern Trust
Illinois
$426K -$12.1K -1,212 -2%
Wells Fargo
17
Wells Fargo
California
$236K -$198K -19,846 -42%
AA
18
ALPS Advisors
Colorado
$230K +$266K +26,662 New
Allspring Global Investments
19
Allspring Global Investments
North Carolina
$230K +$266K +26,675 New
Qube Research & Technologies (QRT)
20
Qube Research & Technologies (QRT)
United Kingdom
$176K +$203K +20,342 New
EP
21
EPIQ Partners
Minnesota
$161K +$186K +18,646 New
AFM
22
Anson Funds Management
Texas
$153K +$177K +17,729 New
Bank of America
23
Bank of America
North Carolina
$148K +$115K +11,485 +206%
UBS Group
24
UBS Group
Switzerland
$135K +$91.2K +9,136 +140%
Millennium Management
25
Millennium Management
New York
$128K +$45.1K +4,513 +44%
1
2 3

IMPL Hedge Fund Activity: Q4 2021 in Review

45 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q4 2021, worth a combined $132M — down 41% from $222M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IMPL positions and 11 closed out — a net gain of 3 holders — while 17 added to existing stakes and 4 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.08M. The largest seller was Ardsley Advisory Partners, exiting entirely with an estimated $3.78M sold.

  • 45 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q4 2021, up from 44 in Q3 2021.
  • Funds reported $132M of Impel Pharmaceuticals Inc. Common Stock stock for Q4 2021, down 41% quarter-over-quarter.
  • 14 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q4 2021 and 11 closed out, a net change of +3 holders.
  • The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q4 2021 was Point72 Asset Management, an estimated $2.08M added.
  • The largest Impel Pharmaceuticals Inc. Common Stock seller in Q4 2021 was Ardsley Advisory Partners, an estimated $3.78M sold.

Based on aggregated 13F filings for Q4 2021.